Fundraising Fox

HiFiBiO Therapeutics

Founded 2013 · 36 employees on LinkedIn · 7 known investors

Find your way into HiFiBiO Therapeutics

265 people in our graph share verified history with the HiFiBiO Therapeutics team — schools, employers, funds. One of them is your warm intro.

Dean Hlushkounlockedknows Liang Schweizer · together at University of Minnesota (overlapped)
knows the team · via University of Science and Technology of China
knows the team · via University of Minnesota
×2knows the team · via Harvard Business School Executive Education
×3knows the team · via Memorial Sloan-Kettering Cancer Center, Varmus lab
×3knows the team · via University of Zurich

HiFiBiO Therapeutics develops immunotherapies for patients with high unmet medical needs, using its Drug Intelligence Science (DIS) platform that combines single cell technology with AI/ML analytics. The platform supports target discovery, antibody selection, and predictive biomarker identification for drug development.

AI & Machine LearningBiotechHealthtech

Founders & leadership

HiFiBiO Therapeutics was founded in 2013 by Liang Schweizer.

LSLiang Schweizer
Liang SchweizerinFounder and President2025–2026Liang Schweizer is the founder of HiFiBiO Therapeutics, which develops immunotherapies using a Drug Intelligence Science platform that integrates single-cell technology with artificial intelligence. Schweizer has expertise in drug discovery and development, single-cell technology, oncology, and immunovirology.

Investors · 7

B Capital GroupManhattan Beach · $10M – $50M
B4 Capital$10M – $50M
Trinity Innovation Bioventure SingaporeSingapore
IDG CapitalreportedHong Kong · $3M – $200M
Legend CapitalreportedBeijing · $2.9M – $156M
LYFE CapitalreportedMenlo Park
Sequoia CapitalreportedMenlo Park · $4.4M – $214M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

3 people who came through HiFiBiO Therapeutics went on to found or lead other companies.

Helmuth van EsStrategic and Scientific AdvisorFounded Antabio +1Liang SchweizerFounderFounded Harbour BioMedGeoff SmithChief Technology AdvisorFounded Syndex

In the news

HiFiBiO raises series D funds to advance immuno-oncology candidatespharmaceutical-technology.com · Jun 2021HiFiBiO gets high-five from investors with $75M series D to bring 2 programs into clinic | Fierce Biotechfiercebiotech.com · Jun 2021HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic - HiFiBio Therapeuticshifibio.com · Jun 2021HiFiBiO Therapeutics receives $67m in Series C funding | AVCJavcj.com · Aug 2019HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders - HiFiBio Therapeuticshifibio.com · May 2018HiFiBiO raises $37.5M in series B following 2017’s management shuffle | Fierce Biotechfiercebiotech.com · May 2018

Frequently asked questions

What does HiFiBiO Therapeutics do?
HiFiBiO Therapeutics develops immunotherapies for patients with high unmet medical needs, using its Drug Intelligence Science (DIS) platform that combines single cell technology with AI/ML analytics. The platform supports target discovery, antibody selection, and predictive biomarker identification for drug development.
Who founded HiFiBiO Therapeutics?
HiFiBiO Therapeutics was founded by Liang Schweizer in 2013.
Who are HiFiBiO Therapeutics's investors?
HiFiBiO Therapeutics's investors include B Capital Group, B4 Capital, Trinity Innovation Bioventure Singapore, IDG Capital, Legend Capital, LYFE Capital, Sequoia Capital.